Conformational changes in a Vernier zone region: Implications for antibody dual specificity
- PMID: 32526069
- DOI: 10.1002/prot.25964
Conformational changes in a Vernier zone region: Implications for antibody dual specificity
Abstract
Understanding the determinants of antibody specificity is one of the challenging tasks in antibody development. Monospecific antibodies are still dominant in approved antibody therapeutics but there is a significant body of work to show that multispecific antibodies can increase the overall therapeutic effect. Dual-specific or "Two-in-One" antibodies can bind to two different antigens separately with the same antigen-binding site as opposed to bispecifics, which simultaneously bind to two different antigens through separate antigen-binding units. These nonstandard dual-specific antibodies were recently shown to be promising for new antibody-based therapeutics. Here, we physicochemically and structurally analyzed six different antibodies of which two are monospecific and four are dual-specific antibodies derived from monospecific templates to gain insight about dual-specificity determinants. These dual-specific antibodies can target both human epidermal growth factor receptor 2 and vascular endothelial growth factor at different binding affinities. We showed that a particular region of clustered Vernier zone residues might play key roles in gaining dual specificity. While there are minimal intramolecular interactions between a certain Vernier zone region, namely LV4 and LCDR1 of monospecific template, there is a significant structural change and consequently close contact formation between LV4-LCDR1 loops of derived dual-specific antibodies. Although Vernier zone residues were previously shown to be important for humanization applications, they are mostly underestimated in the literature. Here, we also aim to resurrect Vernier zone residues for antibody engineering efforts.
Keywords: Vernier zone; antibody; dual specific; human epidermal growth factor receptor 2 (HER2); specificity; vascular endothelial growth factor (VEGF).
© 2020 Wiley Periodicals LLC.
Similar articles
-
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.Science. 2009 Mar 20;323(5921):1610-4. doi: 10.1126/science.1165480. Science. 2009. PMID: 19299620
-
High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity.PLoS One. 2011 Apr 22;6(4):e17887. doi: 10.1371/journal.pone.0017887. PLoS One. 2011. PMID: 21526167 Free PMC article.
-
Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.Methods Enzymol. 2012;502:25-41. doi: 10.1016/B978-0-12-416039-2.00002-1. Methods Enzymol. 2012. PMID: 22208980
-
Engineering aggregation-resistant antibodies.Annu Rev Chem Biomol Eng. 2012;3:263-86. doi: 10.1146/annurev-chembioeng-062011-081052. Epub 2012 Mar 29. Annu Rev Chem Biomol Eng. 2012. PMID: 22468604 Review.
-
Toward Drug-Like Multispecific Antibodies by Design.Int J Mol Sci. 2020 Oct 12;21(20):7496. doi: 10.3390/ijms21207496. Int J Mol Sci. 2020. PMID: 33053650 Free PMC article. Review.
Cited by
-
Structure-based humanization of a therapeutic antibody for multiple myeloma.J Mol Med (Berl). 2024 Sep;102(9):1151-1161. doi: 10.1007/s00109-024-02470-4. Epub 2024 Jul 25. J Mol Med (Berl). 2024. PMID: 39052065 Free PMC article.
-
Germline-Dependent Antibody Paratope States and Pairing Specific VH-VL Interface Dynamics.Front Immunol. 2021 Aug 10;12:675655. doi: 10.3389/fimmu.2021.675655. eCollection 2021. Front Immunol. 2021. PMID: 34447370 Free PMC article.
-
Mutation of Framework Residue H71 Results in Different Antibody Paratope States in Solution.Front Immunol. 2021 Mar 2;12:630034. doi: 10.3389/fimmu.2021.630034. eCollection 2021. Front Immunol. 2021. PMID: 33737932 Free PMC article.
-
Structural Characterization of Nanobodies during Germline Maturation.Biomolecules. 2023 Feb 17;13(2):380. doi: 10.3390/biom13020380. Biomolecules. 2023. PMID: 36830754 Free PMC article.
References
REFERENCES
-
- Eisen HN. Specificity and degeneracy in antigen recognition: yin and yang in the immune system. Annu Rev Immunol. 2001;19:1-21.
-
- Cohn M. Degeneracy, mimicry and crossreactivity in immune recognition. Mol Immunol. 2005;42(5):651-655.
-
- Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One. 2011;6(4):e17887.
-
- Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301(5638):1374-1377.
-
- Van Regenmortel MH. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit. 2014;27(11):627-639.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous